Member Info for stt1

C40% held by multiple institutions.

Plus some have been increasing since H1 end.

Evidence:

c40% held by multiple institutions

https://www.totallyplc.com/investors/shareholder-information/shareholdings/

Holdings increased:

https://ir.design-portfolio.co.uk/viewer/100/60322

https://ir.design-portfolio.co.uk/viewer/100/60993

Moniman

"New contracts secured in the period contributing £14.8 million of annualised revenue."

£14.8m NEW contracts, announced at H1.

Plus the recently announced £13m, which was 30% uplift on the original.

Mcap only £8.5m

They stated they have £37m cash.

Compare that to the latest published AR, for fy2022, they have total liabilities of £31m.

Cash increase due to recent non-refundable booking fees. Cash will decline as they have regular monthly outgoings as well as project costs. If they had so much cash then why didn't they pay for the new facility themselves instead of clients? Those clients would then be given favourable terms, which could be detrimental for new or other clients.

Trout,

As per my previous post, where's the TR1s? Where's the significant holdings >3% by institutionS?

My previous post:

"There's no evidence of significant buying by institutionS in 2021, 2022, 2023. Where's the TR1s?"

"No evidence of significant holdings > 3% by institutionS."

"Institutions have been buying in for the last 8 months because the story is positive"

Since the CEO was awarded the huge options < a year ago and exercisable in a year. Coincidence?

hundreds of small trades today. Yet there aren't hundreds of PIs. A few larger trades.

GeordieChris,

"I'm sure more and more institutions will soon be getting in on the act"

Despite the company being portrayed as growing strongely for past 3 years:

There's no evidence of significant buying by institutionS in 2021, 2022, 2023. Where's the TR1s?

No evidence of significant holdings > 3% by institutionS.

Institutions take a punt all the time.

GeordieChris,

"I can't think of any other company who in January already has the full year revenue pretty much sewn up already as well as a significant inroad into 2025."

They do it every year. Because of the lead time to setup projects, they know which are planned over the following 12 months ++

The one's coming live currently would have been contracted 12-18months ago. Hence why I say there's a lack strong revenue growth.

This from a year ago, Jan 2023 - same 95% contracted for fy2023 plus some visibility into 2024. Same presentation format as last year.

"Over 95% of 2023 revenue guidance contracted and visibility into 2024. "

"The growing orderbook from new and existing Big Pharma and biotech clients provides excellent forward visibility with over 95% of forecasted revenue for 2023 contracted, and further revenue visibility into 2024. "

https://polaris.brighterir.com/public/hvivo/news/rns/story/w9j9mdx

TheSoundMan,

"They have a contracted Option to take a whole new floor at Canary Wharf when needed, and also an admission that they could expand into another country if they want to (so it's obviously been discussed)."

Any Landlord who has space available will willingly rent it out to you. Pointless having empty floors, producing no income.

The banks have been deserting Canary Wharf. The landlords need to get new tenants in, hence the offer.

In terms of expanding into another country. If there's demand what's stopping another company from setting up in say India/China. The Indians and Chinese could do it swiftly if the demand is there.

As examples, Serum Institute rapidly expanded capacity in India during covid to cope with worldwide demand. Indian/Chinese companies were quick to produce their own covid vaccines.

Why can't other companies enter the Challenge Trials space?

Plus add to the CEO options and purchase 1.5yrs ago, CF also bought over 1m shares at 26.5p 2.5years ago.

The current sp of 28p means CF is now finally back in profit on those buys.

https://polaris.brighterir.com/public/hvivo/news/rns/story/w13k89r

There's also lots of PIs on here who were also holding at higher prices, 40p++, and so need the sp to move higher so they can sell.

Look at the options awarded to the CEO, less than a year ago, exercisable in a year and the conditions attached.

These and the number of shares bought by him, tells you why the company is being talked up.

"The LTIP has been designed to reward, incentivise and retainMr Khan to deliver sustainable growth for shareholders. The deemed date of award is 24 February 2022, which is the date Mr Khan was appointed CEO. Under the LTIP,Mr Khan has been awarded 7,227,273 nominal cost long term incentive options ("LTIP Options " ) over ordinary shares of £0.001 each in the Company.

Vesting of the LTIP Options is conditional upon a three-year total shareholder return ("TSR") performance against an initial 11p reference price. A portion of the LTIP Options will vest on the third anniversary of the date of award subject to the achievement of a minimum 10% CAGR TSR performance increasing on a straight-line basis to vesting in full subject to the achievement of a 22.5% CAGR TSR performance.

https://polaris.brighterir.com/public/hvivo/news/rns/story/x21q5mw/export

CEO also bought 500k shares at 9.8p 1.5 yrs ago.

https://polaris.brighterir.com/public/hvivo/news/rns/story/w13k73r

Berniebasset

"Berniebasset

" HVO at 22% margin should post profit of £12.1m before other revenue streams such as R&D - and the profit could rise to over £13m when accounting for exceptional revenues and the number will increase across 2024."

With HVO, there's no evidence of significant holdings by institutions in 2021, 2022, 2023??

Where's all the TR1 showing significant buying by institutions in 2021, 2022, 2023? There aren't any.

Around c40% of TLY is held by institutions and some were increasing since H1.

Berniebasset

" HVO at 22% margin should post profit of £12.1m before other revenue streams such as R&D - and the profit could rise to over £13m when accounting for exceptional revenues and the number will increase across 2024.

- TLY profit was £6.9m and is expected to fall so whilst revenues are high it's margin and costs base are out of control."

It's your money, you need to invest where you feel comfortable.

HVO mcap £200m, TLY Mcap £8m.

I see more risk to HVO to the downside as a lot of expectations more than factored in and it's being talked up.

The profit could also fall.

The reward for TLY is to the upside as a lot of NHS setbacks are factored in. TLY suffered due to doctors strikes, wage inflation, which are temporary setbacks.

TLY has margins of 21% in elective care and 40% in Company staff wellbeing.

The profits/revenues could rise as the govn/NHS needs to tackle waiting times, given it's the GE this year.

I said the same (overvalued) about trmr at 850p, byot at 10p. Look at them now, crashed to 200p and 0.7p respectively.

The sound man

Obviously as you, trout, Hallsworthy, Moniman. 1gw_ feel the future is great then prove me wrong, load up at 28p, don't sell a single share and hold until the 2028, the year they are forecast £100m revenues.

I've traded these before. Not this time because I believe they are being talked up and for the bear points/red flags I've previously mentioned. If I was trading these this time, I would be selling at 28p.

Obviously you're still backing your conviction and loading up. Unless you're just hoping others do, whilst you sell!!!

Look at the conditions attached to the huge options awarded to the CEO less than a year ago, back dated a year and exercisable in a year. To 'Incentivise'

"The LTIP has been designed to reward, incentivise and retainMr Khan to deliver sustainable growth for shareholders. The deemed date of award is 24 February 2022, which is the date. Mr Khan was appointed CEO. Under the LTIP,Mr Khan has been awarded 7,227,273 nominal cost long term incentive options ("LTIP Options " ) over ordinary shares of £0.001 each in the Company.

Vesting of the LTIP Options is conditional upon a three-year total shareholder return ("TSR") performance against an initial 11p reference price. A portion of the LTIP Options will vest on the third anniversary of the date of award subject to the achievement of a minimum 10% CAGR TSR performance increasing on a straight-line basis to vesting in full subject to the achievement of a 22.5% CAGR TSR performance.

https://polaris.brighterir.com/public/hvivo/news/rns/story/x21q5mw/export

The Sound Man,

"TLY was in the mid-40s 2 years ago (now 4p). What happened and why won't it happen again?"

Exactly my point. HVO crashed to 10p and now 28p. Revenues £56m, Mcap £195. Talked up as CEO has huge options exercisable in a year.

TLY recently won a £13m contract, at national level. Revenues £100m, Mcap £8m.

Everyone needs healthcare.

Backs up my point.

Trout,

"What happened and why won't it happen again?""

You very well know what happened. The shares crashed from mid 40s all the way down to 10p.

The figures today have been largely expected for months. The sp was around 20p in Oct.

£56m revenues, £195m mcap says it all.

This is being talked up.

Rivaldo,

"Cavendish have this morning raised their target price to 38p (from 35p)."

Finncap (now Cavendish) had a tp of 44p not that long ago, didn't they?

So 38p is still lower than that 44p target.

The sp was in the mid 40s around 3 years ago.

What happened and why won't it happen again?

Hardboiledegg

"And that just the increase in cash for the year. HVO cash increased by 8.6million. Tly Market Cap 8.55million."

They get some upfront payment for contracts and so cash from recent contract is included. However, cash will reduce over time as they have ongoing monthly costs as well as project costs. As of the latest Annual Report, they have total liabilities of £31m.

They need regular contract wins to keep going.

Given they have so much cash, why didn't they pay for the new facility by themselves? Instead it was largely paid for by clients. That's likely to have been in return for favourable terms for those clients. Those who pay get favourable treatment, really?. That's a questionable business model.

It immediately is a disadvantage for new clients or those who didn't pay.

You mention TLY mcap of £8m. Looking at their cash. They had £1.7m cash as of end H1, received a further £2.5m soon after H1 end and crucially have regular monthly income from the NHS and recently awarded a £13m contract. Revenues already £100m. As you rightly say, £8m mcap.

From today's TU:

". This increase in cash generation is due to improved margins and

the upfront non-refundable quarantine booking fee from new contracts."

https://polaris.brighterir.com/public/hvivo/news/rns/story/xopzn1r/export

Shandypants,

even your imaginary conversation is 'pants'!!!

"I can imagine the conversation Mo - why should i become CEO if you sell it within a couple of years?"

MO was already a CEO for a year when the huge 7m options were awarded to him. So your conversation as to why he should BECOME a CEO is rubbish.

"To give you some protection here are a generous option package. You get them if the business/shares performed well and/OR if it gets sold."

Last Feb, when the huge options were awarded, the sp was around 22p. It's now around 27p, so only 20% up and that's following lots of media tips. Yet, despite the sp being around 22p, the reference price is 1/2 last year's Feb sp at 11p.

The fact is Mo's huge 7m options were back dated by a year and are exercisable in a year.

If you look at the huge options and the terms of the incentive, it's obvious these are being talked up.

The cash and liability figures are from the company own update and Annual Report.

We'll know tomorrow (update) if they publish an up to date cash figure, as of 31st December 2023.